Pfizer Limited
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vi… Read more
Pfizer Limited (PFIZER) - Net Assets
Latest net assets as of September 2025: ₹38.48 Billion INR
Based on the latest financial reports, Pfizer Limited (PFIZER) has net assets worth ₹38.48 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹46.06 Billion) and total liabilities (₹7.57 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹38.48 Billion |
| % of Total Assets | 83.56% |
| Annual Growth Rate | 13.42% |
| 5-Year Change | 76.24% |
| 10-Year Change | 99.12% |
| Growth Volatility | 46.53 |
Pfizer Limited - Net Assets Trend (2005–2025)
This chart illustrates how Pfizer Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pfizer Limited (2005–2025)
The table below shows the annual net assets of Pfizer Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹42.17 Billion | +17.30% |
| 2024-03-31 | ₹35.96 Billion | +12.10% |
| 2023-03-31 | ₹32.07 Billion | +11.97% |
| 2022-03-31 | ₹28.64 Billion | +19.70% |
| 2021-03-31 | ₹23.93 Billion | -29.52% |
| 2020-03-31 | ₹33.95 Billion | +12.76% |
| 2019-03-31 | ₹30.11 Billion | +12.23% |
| 2018-03-31 | ₹26.83 Billion | +10.93% |
| 2017-03-31 | ₹24.19 Billion | +14.21% |
| 2016-03-31 | ₹21.18 Billion | +7.35% |
| 2015-03-31 | ₹19.73 Billion | +199.66% |
| 2014-03-31 | ₹6.58 Billion | -61.14% |
| 2013-03-31 | ₹16.94 Billion | +29.87% |
| 2012-03-31 | ₹13.05 Billion | +12.14% |
| 2011-03-31 | ₹11.63 Billion | +17.01% |
| 2010-03-31 | ₹9.94 Billion | +10.35% |
| 2009-03-31 | ₹9.01 Billion | +38.69% |
| 2008-03-31 | ₹6.50 Billion | +47.75% |
| 2007-03-31 | ₹4.40 Billion | +16.97% |
| 2006-03-31 | ₹3.76 Billion | +10.73% |
| 2005-03-31 | ₹3.40 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pfizer Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1164.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹24.36 Billion | 57.76% |
| Common Stock | ₹457.50 Million | 1.08% |
| Other Comprehensive Income | ₹4.15 Billion | 9.84% |
| Other Components | ₹13.21 Billion | 31.31% |
| Total Equity | ₹42.17 Billion | 100.00% |
Pfizer Limited Competitors by Market Cap
The table below lists competitors of Pfizer Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The RealReal Inc
F:6RR
|
$824.16 Million |
|
Pan Jit International Inc
TW:2481
|
$824.61 Million |
|
Chengdu ALD Aviation Manufacturing Corp
SHE:300696
|
$825.06 Million |
|
Banque Cantonale de Geneve
SW:BCGE
|
$825.51 Million |
|
Hubei Tech Semiconductors Co
SHE:300046
|
$823.72 Million |
|
Shanghai Feilo Acoustics Co Ltd
SHG:600651
|
$823.44 Million |
|
Viglacera Corp JSC
VN:VGC
|
$823.17 Million |
|
Lovisa Holdings Ltd
AU:LOV
|
$822.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pfizer Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 35,955,400,000 to 42,174,100,000, a change of 6,218,700,000 (17.3%).
- Net income of 7,676,000,000 contributed positively to equity growth.
- Dividend payments of 1,602,500,000 reduced retained earnings.
- Other comprehensive income increased equity by 1.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹7.68 Billion | +18.2% |
| Dividends Paid | ₹1.60 Billion | -3.8% |
| Other Comprehensive Income | ₹1.00 | +0.0% |
| Other Changes | ₹145.20 Million | +0.34% |
| Total Change | ₹- | 17.30% |
Book Value vs Market Value Analysis
This analysis compares Pfizer Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.13x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 41.53x to 5.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹113.78 | ₹4725.50 | x |
| 2006-03-31 | ₹125.99 | ₹4725.50 | x |
| 2007-03-31 | ₹135.96 | ₹4725.50 | x |
| 2008-03-31 | ₹217.73 | ₹4725.50 | x |
| 2009-03-31 | ₹301.96 | ₹4725.50 | x |
| 2010-03-31 | ₹333.21 | ₹4725.50 | x |
| 2011-03-31 | ₹389.88 | ₹4725.50 | x |
| 2012-03-31 | ₹437.21 | ₹4725.50 | x |
| 2013-03-31 | ₹567.81 | ₹4725.50 | x |
| 2014-03-31 | ₹143.92 | ₹4725.50 | x |
| 2015-03-31 | ₹431.26 | ₹4725.50 | x |
| 2016-03-31 | ₹462.95 | ₹4725.50 | x |
| 2017-03-31 | ₹528.72 | ₹4725.50 | x |
| 2018-03-31 | ₹586.49 | ₹4725.50 | x |
| 2019-03-31 | ₹658.22 | ₹4725.50 | x |
| 2020-03-31 | ₹742.18 | ₹4725.50 | x |
| 2021-03-31 | ₹523.07 | ₹4725.50 | x |
| 2022-03-31 | ₹626.10 | ₹4725.50 | x |
| 2023-03-31 | ₹701.08 | ₹4725.50 | x |
| 2024-03-31 | ₹785.94 | ₹4725.50 | x |
| 2025-03-31 | ₹921.88 | ₹4725.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pfizer Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.20%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 33.65%
- • Asset Turnover: 0.46x
- • Equity Multiplier: 1.16x
- Recent ROE (18.20%) is below the historical average (18.81%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 13.13% | 7.52% | 1.14x | 1.54x | ₹106.34 Million |
| 2006 | 18.81% | 11.23% | 1.09x | 1.53x | ₹331.37 Million |
| 2007 | 26.21% | 15.35% | 1.07x | 1.59x | ₹657.62 Million |
| 2008 | 52.33% | 48.71% | 0.80x | 1.34x | ₹2.75 Billion |
| 2009 | 33.25% | 43.95% | 0.62x | 1.22x | ₹2.09 Billion |
| 2010 | 13.77% | 17.72% | 0.64x | 1.21x | ₹374.50 Million |
| 2011 | 14.52% | 19.25% | 0.63x | 1.19x | ₹525.32 Million |
| 2012 | 12.99% | 15.51% | 0.69x | 1.21x | ₹389.73 Million |
| 2013 | 29.70% | 53.08% | 0.46x | 1.22x | ₹3.34 Billion |
| 2014 | 10.60% | 3.77% | 2.00x | 1.40x | ₹39.78 Million |
| 2015 | 3.54% | 3.77% | 0.71x | 1.32x | ₹-1.27 Billion |
| 2016 | 14.40% | 15.16% | 0.69x | 1.38x | ₹931.82 Million |
| 2017 | 13.92% | 17.13% | 0.60x | 1.35x | ₹948.92 Million |
| 2018 | 13.42% | 18.29% | 0.53x | 1.38x | ₹917.50 Million |
| 2019 | 14.25% | 20.61% | 0.53x | 1.31x | ₹1.28 Billion |
| 2020 | 14.99% | 23.66% | 0.49x | 1.30x | ₹1.70 Billion |
| 2021 | 20.79% | 22.21% | 0.69x | 1.36x | ₹2.58 Billion |
| 2022 | 21.39% | 23.46% | 0.67x | 1.36x | ₹3.26 Billion |
| 2023 | 19.45% | 25.73% | 0.61x | 1.25x | ₹3.03 Billion |
| 2024 | 15.33% | 25.14% | 0.52x | 1.18x | ₹1.92 Billion |
| 2025 | 18.20% | 33.65% | 0.46x | 1.16x | ₹3.46 Billion |
Industry Comparison
This section compares Pfizer Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $5,554,352,459
- Average return on equity (ROE) among peers: 22.36%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pfizer Limited (PFIZER) | ₹38.48 Billion | 13.13% | 0.20x | $823.98 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $16.96 Billion | 22.18% | 0.80x | $1.16 Billion |
| Kopran Limited (KOPRAN) | $1.09 Billion | 9.86% | 1.43x | $31.83 Million |
| Marksans Pharma Limited (MARKSANS) | $9.05 Billion | 26.35% | 0.36x | $405.73 Million |
| NGL Fine-Chem Limited (NGLFINE) | $160.59 Million | 15.04% | 1.05x | $40.08 Million |
| Sanofi India Limited (SANOFI) | $17.36 Billion | 17.53% | 0.46x | $361.36 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.08 Billion | 79.43% | 0.66x | $319.07 Million |
| SENORES PHARMACEUTICALS L (SENORES) | $94.96 Million | 7.21% | 0.53x | $159.44 Million |
| SMS Pharmaceuticals Limited (SMSPHARMA) | $2.22 Billion | 9.19% | 1.30x | $97.10 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $982.22 Million | 14.46% | 1.13x | $30.49 Million |